Autologous hematopoietic progenitor SCT (HPCT) has been studied both as a consolidative and salvage maneuver in mantle-cell lymphoma (MCL), and may improve failurefree survival rates as well as overall survival. We describe 21 patients with MCL who received autologous HPCT at Emory University Hospital as part of the primary treatment strategy. Sixteen patients were in CR1 and five in PR1 at the time of HPCT. The most commonly used induction chemotherapy was the hyper-CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) regimen with or without rituximab. At the last follow-up, 17 patients were in continuous CR, and there were four relapses. There were no transplant-related deaths. With a median follow-up of 54 months from HPCT, 5-year progression-free survival and overall survival are 73% and 76%, respectively. Our retrospective analysis provides the longest follow-up to date for patients with MCL who received an autologous HPCT as part of primary treatment. This lengthy follow-up helps define the natural course of MCL after autologous transplantation.
Introduction
Since the formal recognition of mantle-cell lymphoma (MCL) as a distinct clinical and pathologic entity in 1993, as part of the Revised European American Lymphoma (REAL) classification, 1 it has become clear that the chemotherapy regimens (for example, CHOP) typically used for non-Hodgkin's lymphoma are generally not curative. 2 Although patients with MCL may respond well to the initial chemotherapy, relapse is inevitable and usually occurs soon after the completion of initial courses of therapy. The addition of rituximab to cytotoxic chemotherapy regimens has improved the response rates, but the impact on longterm survival remains to be demonstrated. 3, 4 Aggressive regimens, such as hyper CVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone) plus rituximab, consistently produce high response rates, [5] [6] [7] [8] and the followup to date appears promising.
Autologous hematopoietic progenitor SCT (HPCT) has been studied both as a consolidative and salvage maneuver, and may improve failure-free survival rates as well as overall survival. 6, [9] [10] [11] The superior outcome of patients transplanted in CR1 has been a consistent finding in most reported series, and argues for the application of high-dose therapy with autologous HPCT as part of the primary treatment. 5, [12] [13] [14] [15] [16] Nevertheless, it remains unclear whether autologous HPCT is actually curative, and the optimal timing of transplantation remains a point of debate.
Long-term follow-up of patients is important to assess whether the risk of relapse continues for years beyond the initial treatment timeline. Our analysis provides the longest published follow-up to date for patients receiving autologous HPCT for MCL, and indicates that autologous HPCT may produce long periods of disease-free survival, and perhaps even cure, for a substantial fraction of patients undergoing transplantation as part of the initial treatment strategy.
Materials and methods

Patient population and definitions
Between 1995 and 2006, 26 consecutive patients underwent autologous HPCT for documented MCL at Emory University Hospital. For the purposes of this retrospective analysis, we focused on the 21 patients who received an autologous HPCT as part of the primary treatment strategy. Data collection and analysis were conducted in conjunction with an IRB-approved transplant research database permitting retrospective outcome analysis of patients undergoing transplantation at our center.
The diagnosis of MCL was confirmed at our center by primary pathologic and flow cytometric examination, or by a review of outside specimens. The diagnosis was made according to standard histologic, flow cytometric and immunohistochemical criteria and was confirmed in all patients by morphology and flow cytometry (a clonal B-cell phenotype positive for CD5, CD19, CD20 and FMC-7, but negative for CD23). Cytogenetics and cyclin D1 overexpression data were available in 13 patients. All patients were staged at diagnosis using Ann Arbor staging criteria for non-Hodgkin's lymphoma. Responses (CR and PR) were classified using the revised International Workshop Standard Response Criteria. 17, 18 HPC collection and cryopreservation Hematopoietic progenitor cells for transplant were obtained either by apheresis during the recovery phase after chemotherapy (20 patients), or by BM harvest (one patient). HPC products were cryopreserved at À701C in DMSO according to standard methods without ex vivo purging or cellular depletion maneuvers. 19 Conditioning, transplantation and supportive care Pre-transplant conditioning consisted of either high-dose BU (a starting dose of 1 mg/kg/dose) targeted to a total area under the curve (AUC) over 16 planned doses of 20 000 þ / À2000 mmol Â min/liter, CY (120 mg/kg) and etoposide (30 mg/kg) or TBI (1200 cGy) and CY (120 mg/kg).
During the transplant period, patients were treated in single rooms with positive pressure and high efficiency particulate air (HEPA)-filtered airflow. Antimicrobial prophylaxis during the neutropenic period consisted of ciprofloxacin, penicillin or clarithromycin, fluconazole and acyclovir. Patients also received Pneumocystis jiroveci prophylaxis from day 30 until 6 months post transplant. Transfusions and supportive care during the transplant period were provided according to the standard institutional guidelines.
Analysis and follow-up
Surviving patients were censored at the date of last followup documented by an imaging study, laboratory results, clinic visit or contact with the patient or his/her physician. Follow-up in the transplant clinic generally occurred at 6-month intervals for at least 5 years post transplant. Relapse was documented by sequential imaging studies and/or biopsy.
Overall survival was calculated both from the date of diagnosis and the date of transplant; progression-free survival was calculated from the date of transplant. Kaplan-Meier survival curves were generated and statistical analyses performed using SPSS 14.0 for Windows (SPSS, Chicago, IL, USA).
Results
Patient population
Between 1995 and 2006, 26 patients with biopsy-proven MCL underwent autologous transplantation at the Winship Cancer Institute/Emory University Hospital. This analysis focuses on the 21 patients who were transplanted in CR1 or PR1, as part of the initial treatment plan. Pretransplant characteristics of these 21 patients are shown in Table 1 .
Pre-transplant therapy and disease status at transplantation All 21 patients received high-dose chemotherapy and autologous transplantation as part of the initial treatment plan, including 16 patients transplanted in CR1 and five patients in PR1. Before the transplant maneuver, 12 patients (57%) had received at least one dose of rituximab. The most common chemotherapy for induction or salvage therapy was the hyper-CVAD regimen, used in 16 patients (76%). Of these 16 patients, five received hyper CVAD without rituximab (median number of four cycles, range: 4-6) and 11 received hyper CVAD with rituximab (median number of four cycles, range: 4-6).
HPC source and conditioning therapy
Peripheral blood HPCs were collected in 20 patients (95%). HPCs were collected by large volume apheresis (20 l) performed daily at the time of hematopoietic recovery following chemotherapy plus growth factor mobilization. The most common mobilization chemotherapy regimens were hyper CVAD (12 patients) and CY (eight patients). Rituximab was given as part of the mobilization regimen in 10 patients (47%). A BM harvest was performed in one patient (5%) following the failure to collect an adequate number of HPCs by apheresis. Pre-transplant conditioning therapy consisted of targeted BU, CY and etoposide in 19 patients (90%) and TBI plus CY in two patients (10%). Rituximab was not given as part of the conditioning regimen for any patient.
Engraftment
All patients achieved neutrophil engraftment (defined as ANC41000/mcl for 3 consecutive days) at a median of 16 days post transplant (range: 10-90 days). The longest time to neutrophil engraftment (90 days) occurred in the one patient who received an autologous BMT following the failed peripheral blood HPC collection.
All patients achieved platelet engraftment (defined as a platelet count of 420 000/mcl for 7 consecutive days without platelet transfusion) at a median of 19 days post transplant (range: 9-191 days). One patient continues to be thrombocytopenic with a platelet count of 30 000-60 000/ mcl 3 years post transplant, but is platelet transfusionindependent.
Adverse events following transplantation
The most common post-transplant complications were infectious. Three patients (14%) had documented infectious complications during the neutropenic period including one patient with an indwelling line infection, one patient with sinusitis and one patient with Clostridium difficile colitis. Transient fever during the neutropenic period without an identifiable organism or source occurred in an additional three patients (14%).
There were no cases of grades III-IV nonhematologic toxicity and no transplant-related deaths. All patients were alive at day 100 post transplant.
Post-transplant maintenance therapy
Three patients (14%) received post-transplant rituximab for a median of five cycles (range: 4-6). Two of these three patients were in CR1 at the time of transplant.
Outcomes, follow-up and survival after transplant All patients achieved a CR by restaging studies performed between day 30 and day 100 post transplant. Median follow-up for surviving patients is 64 months (5.3 years) from diagnosis (range: 20-142 months) and 56 months (4.7 years) from transplantation (range: 13-125 months).
Four patients (19%) have relapsed at a median time of 29.6 months (range: 22-108 months) after transplant. The latest relapse occurred 9 years after the initial diagnosis, and that patient is currently in a positron emission tomography (PET) scan-negative CR following salvage chemotherapy and a second autologous transplant. Seventeen patients are alive, 16 in continuous CR. The longest post transplant follow-up to date in our population is 10.44 years from HPCT.
There have been four deaths (19%) in this patient population. One death occurred in continuous CR as a result of sepsis after hip replacement surgery approximately 4 years after transplant. All other deaths occurred following relapse.
Survival analysis and associated factors
Kaplan-Meier estimates of 5-year overall survival for all patients from diagnosis and transplant were 80 and 76%, respectively (Figure 1) . In a univariate analysis, there was a trend toward the improved overall survival in younger patients (data not shown), but this was not statistically significant. The 5-year relapse-free survival from HPCT for all patients was 73% (Figure 2) . Factors not associated with either overall or relapse-free survival included the initial disease stage, BM involvement at diagnosis, type of prior chemotherapy and administration of rituximab before or after transplantation.
Discussion
Although complete responses are seen following conventional-dose chemotherapy regimens containing rituximab in patients with MCL, these responses are generally not durable and most published reports have short follow-up. The literature supports the performance of autologous HPCT in CR1, 12, 13 but the limited follow-up in most published series precludes the determination of long-term benefit. Our median follow-up is 64 months (20-142 months) from diagnosis and 56 months (13-125 months) from transplant and is the longest follow-up to date for patients who received autologous HPCT. Until now, the longest published median follow-up was 49 months. 20 Therefore, we are able to provide relapse-free and overall survival data that suggest the curative potential of autologous transplantation in a subset of patients with MCL ( Table 2) .
The only prospective randomized trial for autologous HPCT in MCL was published by Dreyling et al. 21 in 2005, demonstrating prolonged progression-free survival in patients who received early consolidation with autologous HPCT. The progression-free survival and overall survival at 3 years were 54 and 83%, respectively, which are slightly lower than our reported survival. This difference may be Early autologous transplantation for mantle-cell lymphoma S Murali et al attributable to the use of CHOP-based induction chemotherapy before autologous HPCT in the Dreyling analysis as opposed to the more aggressive hyper-CVAD regimen that was used in most of our patients.
The majority of our patients (16 patients, 76%) received the hyper-CVAD regimen with or without rituximab before transplant. A recent meta-analysis suggests that rituximab plus chemotherapy is superior to chemotherapy alone in improving overall survival in MCL. 22 In addition, there are emerging data that the hyper-CVAD þ /À rituximab regimen may improve overall survival when compared with a CHOP-like induction. 23 The small number of patients in our series does not permit the evaluation of the relative efficacy of rituximab in this setting.
One of the most important limitations of our analysis is that it includes only patients who went on to autologous HPCT as part of the primary treatment strategy. Using data from our institutional tumor registry, 23 patients aged o70 received primary therapy for MCL at Emory University during the time period of this analysis. This number does not include patients who received most of their therapy from an outside physician and were then referred specifically for transplant. Of the 23 patients, 15 (65%) were able to go on to autologous HPCT in CR1/ PR1. Of the eight patients who did not go on to autologous HPCT, four failed to mobilize adequate numbers of stem cells and four had toxicities and/or progressive disease that precluded HPCT. These data suggest that over half of the newly diagnosed patients up to the age of 70 years with MCL are able to complete an aggressive initial treatment strategy that includes planned autologous HPCT. Furthermore, our series documents that autologous HPSCT is well tolerated and can be performed safely, even in older patients.
The utility of autologous HPSCT in CR1 as a consolidative maneuver is well documented. 9, 12 In our patient population, 16 patients (76%) were in CR1 at the time of transplant and five patients (24%) were in PR1. There was one biopsy-proven late relapse 9 years post transplant; the remaining three relapses occurred 1.8, 2 and 2.9 years after transplant. Currently, nine patients are alive and in continued CR beyond 4.5 years, and two patients are more than 10 years post transplant. Only one prior study to date has a similar length of follow-up with similar progression-free and overall survival rates. 24 Our analysis did not detect differences in overall or progression-free survival between patients who achieved a CR or PR before HPCT, although the numbers in our analysis are too small to draw conclusions on this point. Nevertheless, our results and lengthy follow-up indicate that both CR1 and PR1 patients may become long-term survivors following early autotransplantation.
The role of allogeneic HPCT is still being defined. There are several reports to suggest that although the maneuver may be curative, treatment-related morbidity and mortality related to GVHD make it difficult to recommend this strategy for most patients in CR1. 25 Allogeneic transplantation is certainly a reasonable consideration for patients who relapse after autologous HPCT. 26 Furthermore, reduced-intensity conditioning regimens allow allogeneic transplantation of a broader group of patients, and available data suggest that durable responses may be achieved in a substantial proportion of patients with relapsed or refractory MCL, suggesting that MCL is subject to potent GVL effects. 14, [27] [28] [29] [30] Historically, MCL has been characterized by relatively brief remissions and short survival times relative to other non-Hodgkin's lymphoma subtypes. The developments of more aggressive induction chemotherapy regimens and monoclonal antibody therapy and advances in both transplantation and supportive care have improved the outlook for patients with MCL. The timing of relapses in our autologous transplant population (including one Table 2 Selected trials of autologous transplantation in MCL: a comparison of median follow-up, overall survival and progression-free survival Early autologous transplantation for mantle-cell lymphoma S Murali et al relapse 9 years post-HPCT) leaves open the question of how long patients are at continued risk of relapse and hence of how many patients may actually be cured by high-dose therapy. The role of immunotherapy as part of the treatment plan is also still being defined. The addition of an anti-CD20 radioimmunoconjugate to induction chemotherapy may improve short-term failure-free survival, but the impact on long-term survival as well as the rates of late complications such as myelodysplastic syndromes or acute leukemia remains to be seen. 31 Some form of maintenance therapy, such as an antitumor vaccine or other post-transplant immunotherapy, might be of benefit in this challenging patient population and help define a potential 'curative' strategy.
